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Abstract
Aims/hypothesis The UK Prospective Diabetes Study
(UKPDS) risk engine has become a standard for cardio-
vascular risk assessment in type 2 diabetes mellitus. Skin
autofluorescence was recently introduced as an alternative
tool for cardiovascular risk assessment in diabetes. We
investigated the prognostic value of skin autofluorescence
for cardiovascular events in combination with the UKPDS
risk engine in a cohort of patients with type 2 diabetes
managed in primary care.
Methods Clinical, UKPDS risk engine and skin autofluor-
escence data were obtained at baseline in 2001–2002 in
the type 2 diabetes group (n=973). Follow-up data
concerning fatal and non-fatal cardiovascular events
(primary endpoint) were obtained till 2005. Patients were
classified as ‘low risk’ when their 10 year UKPDS risk
score for fatal cardiovascular events was <10%, and ‘high
risk’ if >10%. Skin autofluorescence was measured non-
invasively with an autofluorescence reader. Skin auto-
fluorescence was classified by the median (i.e. low risk <
median, high risk > median).
Results The incidence of cardiovascular events was 119 (44
fatal, 75 non-fatal). In multivariate analysis, skin autofluor-
escence, age, sex and diabetes duration were predictors for
the primary endpoint. Addition of skin autofluorescence
information to that from the UKPDS risk engine resulted in
re-classification of 55 of 203 patients from the low-risk to
the high-risk group. The 10 year cardiovascular event rate
was higher in patients with a UKPDS score >10% when
skin autofluorescence was above the median (55.8% vs
38.9%).
Conclusions/interpretation Skin autofluorescence provides
additional information to the UKPDS risk engine which
can result in risk re-classification of a substantial number
of patients. It furthermore identifies patients who have a
particularly high risk for developing cardiovascular
events.
Keywords Advanced glycation end-products .
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UKPDS UK Prospective Diabetes Study
Introduction
Increased formation and accumulation of advanced glyca-
tion end-products is one of the pathogenetic mechanisms of
accelerated atherosclerosis in type 2 diabetes [1]. Both
crosslinking of proteins by AGEs and receptor-mediated
cellular activation contribute to loss of vascular elasticity
and to propagation and maintenance of inflammation,
contributing to the development of microvascular and
macrovascular disease. The DCCT and subsequent Epide-
miology of Diabetes Interventions and Complications
(EDIC) substudy on skin collagen glycation found that
AGE levels in skin tissue predict long-term diabetic
complications in type 1 diabetes before and after adjust-
ment for HbA1c [2, 3].
Recently, skin autofluorescence (AF) has emerged as a
non-invasive and reproducible tool to estimate the AGE
level of skin tissue. Skin AF has been validated against skin
levels of several specific AGEs and a classic assay for
AGEs—collagen-linked fluorescence—in different popula-
tions (diabetes, renal failure and controls) [4–6]. Skin AF
was consistently shown to be related to micro- and
macrovascular complications in type 2 diabetes, and to be
a strong and independent predictor of cardiovascular
mortality in patients with diabetes mellitus and in patients
receiving haemodialysis [5, 7, 8].
For a cardiovascular (CV) risk biomarker such as skin
AF to be useful in clinical practice, it is mandatory that it
adds information to conventional risk factors or risk models
in unselected cohorts. Several simulation models have been
developed over the last few years to estimate the risk for
future occurrence of diabetes-related complications. The
UK Prospective Diabetes Study (UKPDS) risk engine has
emerged as the most widely used tool to predict complica-
tions in type 2 diabetes [9]. Although it was developed in
newly diagnosed type 2 diabetes, it is now also used in
patients with known diabetes. Still, the incorporation of
established CV risk factors and the derived algorithms, such
as the UKPDS risk engine, do not fully explain CV risk
[10]. Combining the UKPDS risk score and AF might
improve the prediction of CV complications, especially
as AGE accumulation may reflect a distinct biological
pathway in atherogenesis not, or only partly, covered by
other risk factors. Therefore, our aim was to assess the
additional value of skin AF to that obtained from the
UKPDS risk engine for the prediction of CV morbidity
and mortality in patients with relatively recently diag-
nosed, and well-controlled, type 2 diabetes managed in
primary care.
Methods
Patients The previously described cohort of 973 patients
was used for this follow-up study [7]. In short, the cohort
was recruited from participants in the Zwolle Outpatient
Diabetes project Integrating Available Care (ZODIAC)
study, which investigated the effects of a shared-care
project in a primary care population of patients with type 2
diabetes in the eastern part of the Netherlands, starting in
1998 [11]. All known type 2 diabetes patients of 32 general
practitioners who received their diabetes support in the
primary care setting and additionally visited the diabetes
outpatient clinic annually were approached for participa-
tion. Patients were included from May 2001 to May 2002.
The majority were white (97%). Patients with cognitive
disability or a terminal disease were not included in the
ZODIAC study and were, consequently, also ineligible for
the present study. This study was approved by the local
ethical committee. Written informed consent was obtained
from the participants.
Materials and techniques Skin autofluorescence was
assessed at baseline using the Autofluorescence Reader (a
prototype of the current AGE Reader; DiagnOptics,
Groningen, the Netherlands) as described previously [7].
In short, the Autofluorescence Reader illuminates a skin
surface of ∼4 cm2, guarding against surrounding light, with
an excitation light source with peak intensity at ∼370 nm.
Emission light and reflected excitation light from the skin
are measured with a spectrometer in the 300–600 nm range,
using a glass fibre.
Measurements were performed at the volar side of the
arm. AF was calculated by dividing the average emitted
light intensity per nm in the range between 420 and 600 nm
by the average excitated light intensity per nm in the range
between 300 and 420 nm. AF was expressed as arbitrary
units (a.u.), and multiplied by 100. Overall AF measure-
ments, and the mean age-corrected AF per measuring
month, per examiner and per AFR-system did not differ
significantly. Repeated AF measurements taken over a
single day in control participants and diabetic patients
showed an overall Altman error of 5.03%. Intra-individual
seasonal variance among control participants and diabetic
patients showed an Altman error of 5.87%.
Clinical data The methods of baseline clinical data
collection and laboratory assessments have been described
in detail elsewhere, including the definition of a history of
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any microvascular disease (retinopathy, neuropathy and/or
nephropathy) or any macrovascular disease (coronary heart,
cerebrovascular and/or peripheral vascular disease) [7].
Follow-up data, obtained in the period between the
date of the baseline autofluorescence measurement and
1 January 2005, were used in the analyses.
UKPDS risk score The UKPDS risk score (10 year non-
fatal CHD risk, 10 year fatal CHD/stroke risk) was
calculated with the UKPDS risk engine (version 2.0,
www.dtu.ox.ac.uk, accessed 2 January 2007) using the
values of the required variables collected at baseline (single
observations).
Events Fatal or non-fatal events were registered from the
date of inclusion until January 2005. Fatal events were
categorised as: due to CHD, International Classification of
Diseases, ninth revision (ICD-9) codes 410–414, cerebro-
vascular disease 430–438, other CV disease 390–409, 415–
429, 439–459, sudden death 798–798.9 and non-CV deaths
(all other causes). The coded causes of death were
combined as total mortality (all codes) and CV mortality
(390–459 plus sudden death). The following non-fatal CV
events were registered: CHD (myocardial infarction, coro-
nary artery bypass surgery and percutaneous coronary
intervention), major cerebrovascular accidents or peripheral
vascular disease (amputation, percutaneous transluminal
angioplasty, bypass surgery). In the case of multiple non-
fatal CV events during the follow-up period, only the first
event was considered in the study. All cases and time
points of CV death or events were adjudicated by two
independent physicians unaware of the skin AF results,
using the hospital and general practitioner records. The
primary endpoint was ‘any CV event’ (fatal plus non-fatal
CV events), the secondary endpoints were all-cause
mortality plus non-fatal CV events, and all-cause mortality
only.
Statistical analysis The size of the cohort was calculated
before the start of the study in 2001 to allow sufficient CV
events to occur during the follow-up period to detect a 6%
difference in the proportion of patients having and not
having an event (93% vs 87%) [7, 12]. The incidence rates
of endpoints were calculated per 1000 person-years.
Univariate and multivariate Cox regression analyses were
performed for the primary endpoint and the secondary
endpoints. Possible effect-modification of sex, a history of
macrovascular disease, or a history of microvascular
disease on the relation between skin AF and endpoints
was tested by including interaction terms in regression
models.
For the analysis of the possible usefulness of combining
skin AF result with the UKPDS risk score, the participants
were divided into four groups: group 1, those with a 10 year
UKPDS risk for a fatal CV event below 10% and AF below
the median; group 2, those with a 10 year UKPDS risk
below 10% and a skin AF value above the median; group 3,
those with a 10 year UKPDS risk for a fatal CVevent above
10% and AF below the median; and group 4, those with a
10 year UKPDS risk above 10% and a skin AF value above
the median.
The cut-off point of the UKPDS risk score was chosen
because it is used in the Dutch cardiovascular risk
management guidelines 2007 as a treatment-decision cut-
off value [13]. The classification of skin AF above and
below the median was determined previously as a result of
receiver-operating curve (ROC) analyses (non-published
data): ROC curves of skin AF expressed as continuous
variable and using classification defined by median, tertile
and quartile were constructed for the endpoint all-cause
mortality. Median skin AF gave the highest value of AUC:
0.63, 95% CI 0.58–0.69. Other values were: AF on a
continuous scale, AUC 0.61 (95% CI 0.55–0.67); AF >
second tertile, AUC 0.59 (95% CI 0.52–0.65); and AF in
highest quartile, AUC 0.57 (95% CI 0.51–0.64). Therefore,
we used median skin AF in the analysis. For the analysis of
the possible value of adding information on skin AF to the
UKPDS risk score we performed re-classification analyses,
calculated AUCs of two models with and without skin AF
[14, 15] and constructed Kaplan–Meier curves with the
cumulative incidence of events in the four subgroups.
Differences between the Kaplan–Meier curves were tested
using the logrank test.
A p value <0.05 (two-tailed) was considered significant.
A 0.025 increment of AUC was considered clinically
relevant. This study was not powered to reach statistical
significance at an AUC increase of 0.025, which needs a
sample size >10,000 patients (80% power, α=0.05).
Results
Group characteristics Between 2001 and 2002, 973
patients with type 2 diabetes were studied. Six patients
were lost to follow-up. The baseline characteristics of the
remaining 967 patients are detailed in Table 1. The mean
age was 66 years, mean HbA1c 7.0% and mean duration of
diabetes was 6.3 years. The median follow-up period was
1,131 days (interquartile range [IQR] 1,019–1,212 days).
Forty-two patients died from non-CV causes. There were
119 CV events: 44 CV deaths, and 75 non-fatal CV events,
corresponding to an incidence rate of this primary endpoint
of 40.1 per 1,000 person-years. A history of CHD was
present in 204 patients. In these patients, the incidence of
the primary endpoint was 75 per 1,000 person-years at
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follow-up compared with 32 per 1,000 person-years in
patients without a history of CHD.
Validation of UKPDS risk engine For all participants
(including those with a history of CHD), the calculated
median UKPDS risk score in 10 years for the primary
endpoint was 35%. The calculated median UKPDS risk
score in 3.2 years was 12.3%. This expected CV event rate
was not significantly different from the observed rate: 13%
in this study.
Predictors of the primary and secondary endpoints Table 2
shows the univariate HRs for the different endpoints. The
first multivariate model including all items of the UKPDS
risk engine (except atrial fibrillation and ethnicity) plus AF
showed significant HRs for age, diabetes duration and
female sex; skin AF was a significant categorical variable
(below or above median) and skin AF as a continuous
variable for the primary endpoint was nearly significant
(Table 2). Smoking, HbA1c, systolic blood pressure and
lipid profile were not significant. The second multivariate
model consisted of a history of microvascular disease, a
history of a macrovascular disease, 10 year UKPDS risk
score for total fatal CV disease above 10% and AF, and
showed significant HRs for UKPDS risk score and for a
history of macrovascular disease on all endpoints. Signif-
icant HRs were only observed for AF at both secondary
endpoints (Table 2). A history of microvascular complica-
tions was not significant for any endpoint.
There was no effect modification by sex, history of
microvascular complications or history of macrovascular
complications in both the univariate and multivariate
analyses of effects of skin AF on the primary or secondary
end-points.
Additional value of skin AF data Table 3 shows multivar-
iate Cox regression analyses and comparison of AUCs for
models with the UKPDS risk score (cut-off point 10%),
with or without the addition of skin AF (cut-off point
median) for all three endpoints. In model 1, for the primary
endpoint, the AUC of the model including skin AF
increased from 0.581 to 0.618, which is considered
clinically relevant (>0.025), but not significant. For the
second secondary endpoint, the AUC increased significant-
ly to 0.667 (p=0.03). AUC was highest in model 2 (AUC
0.718), which included history of microvascular and
macrovascular complications and skin AF. The AUC of
this model without skin AF was 0.712, so in model 2 AF
made no relevant contribution to the prediction of the
primary endpoint.
Table 4 presents the proportion of patients initially
classified as having a 10 year risk lower or higher than
10% who would be re-classified to a higher or lower risk
category by having a skin AF lower or higher than the
median. It appeared that 55 of 203 persons (27%) with a
calculated 10 year fatal CV risk <10% with the UKPDS risk
engine had an AF above the median, resulting in re-
classification from low to high risk. The calculated 10 year
CV event rate (based on the observed CV events in the first
3.2 years) in this group with low risk according to the
UKPDS risk score and high risk according to skin AF is
17.8%, which is 59% higher than that of the patients with
low UKPDS risk score and skin AF below the median
(11.2%). This difference was not significant (p=0.5).
Within the high-risk group (UKPDS risk score >10%), the
calculated 10 year CV event rate was significantly higher
(55.8%) in patients with skin AF > median compared with
patients with skin AF < median (38.9%), p=0.049.
Table 1 Baseline characteristics of the 967 participants with type 2
diabetes patients for whom follow-up data were available
Characteristic Mean (SD) or %
Age (years) 66 (11)
Male sex (%) 47
Smoking (%) 19
BMI (kg/m2) 29 (5)
Systolic blood pressure (mmHg) 146 (20)
Diastolic blood pressure (mmHg) 81 (10)
Diabetes duration (years) 4.2 (1.6–8.3)a
HbA1c (%) 7.0 (1.3)
Creatinine (µmol/l) 96 (20)
Creatinine clearance (Cockroft formula) (ml/min) 76 (27)
Urinary albumin/creatinine ratio (mg/mmol) 1.47 (0.8–4.1)a
Total cholesterol (mmol/l) 5.2 (1.0)
Cholesterol/HDL-cholesterol ratio 4.3 (1.2)
HDL-cholesterol (mmol/l) 1.3 (0.3)
LDL-cholesterol (mmol/l) 2.9 (0.9)
Triacylglycerols (mmol/l) 2.3 (1.3)




Macrovascular disease (%) 39
CHD 21
Cerebrovascular disease 8
Peripheral vascular disease 22
Skin autofluorescence (a.u.), mean 2.79 (0.8)
Skin autofluorescence (a.u.), median 2.69 (2.26–3.19)a
UKPDS risk score (%) 27.4 (16.6–46.9)a
Values are expressed as mean (SD) or % except where indicated
aMedian and interquartile range
a.u., arbitrary units
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Table 2 Results from the univariate and multivariate Cox regression analyses
Variable Primary endpoint First secondary endpoint Second secondary endpoint
HR 95% CI HR 95% CI HR 95% CI
Univariate analysis
Agea 1.38b 1.18–1.58 1.46b 1.29–1.64 1.78b 1.51–2.05
Female sex 0.64b 0.45–0.92 0.69b 0.51–0.95 0.68 0.44–1.03
Diabetes durationa 1.22b 1.07–1.37 1.21b 1.08–1.34 1.22b 1.05–1.40
Current smoking 1.16 0.75–1.79 1.20 0.83–1.73 1.52 0.94–2.45
BMIa 0.94 0.76–1.12 0.94 0.78–1.09 1.01 0.80–1.22
Hypertension 0.96 0.64–1.43 1.06 0.74–1.52 1.24 0.75–2.07
Systolic blood pressurea 1.08 0.90–1.26 1.10 0.95–1.25 1.17 0.97–1.38
Diastolic blood pressurea 0.83 0.65–1.01 0.80 0.64–0.95 0.84 0.64–1.06
HbA1c
a 1.04 0.87–1.23 1.03 0.89–1.20 1.03 0.83–1.26
Creatininea 1.26b 1.12–1.40 1.26b 1.14–1.38 1.30b 1.15–1.45
Total cholesterola 0.96 0.80–1.15 0.87 0.74–1.02 0.80 0.64–1.00
Chol/HDL ratioa 1.17 0.99–1.37 1.13 0.97–1.30 1.04 0.84–1.28
HDL-cholesterola 0.86 0.78–1.02 0.85b 0.78–0.97 0.89 0.78–1.10
LDL-cholesterola 0.97 0.81–1.16 0.94 0.80–1.10 0.95 0.77–1.82
Skin AF > median 1.80b 1.24–2.62 2.05b 1.48–2.84 3.13b 1.93–5.08
History of peripheral vascular disease 3.19b 2.22–4.58 3.01b 2.21–4.12 3.96b 2.59–6.06
History of CHD 2.48b 1.71–3.60 2.18b 1.57–3.01 1.98b 1.26–3.10
Albuminuria 1.76b 1.21–2.56 1.85b 1.35–2.55 2.50b 1.63–3.82
Neuropathy 1.49b 1.03–2.16 1.51b 1.09–2.07 1.85b 1.20–2.84
Retinopathy 1.23 0.81–1.88 1.04 0.71–1.53 1.17 0.70–1.95
Microvascular complications 1.25 0.87–1.81 1.33 0.97–1.83 2.04b 1.29–3.24
Macrovascular complications 4.33b 2.91–6.45 3.26b 2.36–4.52 2.99b 1.93–4.63
10 year CHD riska,c 2.19b 1.48–3.59 2.32b 1.63–3.56 3.55b 2.04–6.84
10 year risk of fatal CV eventa,c 1.80b 1.34–2.60 1.90b 1.46–2.61 2.62b 1.75–4.25
10 year risk of fatal CV event >10%c 3.97b 1.94–8.13 3.57b 1.98–6.42 4.71b 1.91–11.63
Multivariate analysis
Model 1
Agea 1.34b 1.11–1.57 1.41b 1.21–1.61 1.71b 1.40–2.02
Diabetes durationa 1.18b 1.01–1.35 1.15b 1.01–1.29 1.07 0.87–1.27
Female sex 0.59b 0.40–0.86 0.65b 0.46–0.90 0.59b 0.37–0.94
Smoking 1.18 0.75–1.86 1.24 0.84–1.82 1.71b 1.03–2.82
HbA1c
a 0.97 0.79–1.18 0.98 0.82–1.16 1.00 0.78–1.26
Systolic blood pressurea 1.02 0.82–1.20 1.02 0.87–1.18 1.10 0.85–1.36
Total cholesterola 1.06 0.88–1.28 0.96 0.82–1.14 0.88 0.70–1.10
HDL-cholesterola 0.86 0.77–1.04 0.86 0.78–1.00 0.94 0.80–1.24
Skin AF 1.46 0.97–2.20 1.57b 1.10–2.25 2.05b 1.22–3.45
Model 2
Microvascular complications 0.86 0.59–1.26 0.94 0.68–1.30 1.40 0.88–2.25
Macrovascular complications 3.79b 2.51–5.72 2.74b 1.96–3.83 2.16b 1.38–3.40
10 year risk for fatal CV event >10%c 2.79b 1.34–5.84 2.50b 1.36–4.58 2.78b 1.10–7.03
Skin AF 1.21 0.82–1.79 1.46b 1.04–2.05 2.18b 1.32–3.59
Primary endpoint: fatal + non-fatal CVevents; first secondary endpoint: non-fatal CVevents + all-cause mortality; second secondary endpoint: all-
cause mortality
a HR for continuous variables expressed per SD increase
b Significant HR
c Calculated with the UKPDS risk engine
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Figure 1 shows Kaplan–Meier survival curves for the
primary end-point of the four groups. For this endpoint,
survival was significantly different between group 4 and all
other groups (1, p<0.001; 2, p<0.05; 3, p<0.05), and
between group 3 and group 1 (p<0.01). Similar differences
between groups were found in the analyses for secondary
endpoints (survival curves not shown). When participants
with a known history of CHD at baseline were excluded
from an analysis, similar differences between the same
groups were also found for the primary end-point, except
that the difference between groups 3 and 4 lost significance
(p=0.053).
Discussion
This study shows that skin autofluorescence is of additional
clinical value in the evaluation of risk of fatal and non-fatal
CV events and total mortality in type 2 diabetes mellitus. It
is concluded that skin autofluorescence identifies a patient
subgroup with an increased event rate within the group of
patients at high risk for a fatal CV event (> 10% within the
next 10 years) calculated with the UKPDS risk engine. The
patient group with a UKPDS risk score >10% and a skin
AF value above the median had a 10 year event rate
(55.8%) significantly higher than that of the group with
Table 3 Multivariate Cox regression analyses and comparison of AUCs for models with the UKPDS risk score above 10%, with or without the
addition of skin AF
Primary endpoint First secondary endpoint Second secondary endpoint
HR 95% CI AUC p valuea HR 95% CI AUC p value HR 95% CI AUC p value
Model 1
10 year risk for fatal CV event >10%b 3.97 1.94–8.13 0.581 3.57 1.98–6.42 0.581 4.71 1.91–11.6 0.583
10 year risk for fatal CV event >10%b 3.51 1.70–7.25 3.03 1.67–5.49 3.56 1.43–8.86
Skin AF > median 1.52 1.05–2.22 0.618 0.295 1.75 1.26–2.44 0.635 0.083 2.64 1.62–4.31 0.667 0.031
Model 2
Microvascular complications 0.88 0.61–1.28 0.98 0.71–1.36 1.53 0.96–2.44
Macrovascular complications 3.92 2.61–5.87 2.91 2.09–4.06 2.45 1.57–3.83
10 year risk for fatal CV event >10%b 2.95 1.42–6.12 0.712 2.77 1.52–5.04 0.682 3.41 1.36–8.52 0.689
Microvascular complications 0.86 0.59–1.26 0.94 0.68–1.30 1.40 0.88–2.25
Macrovascular complications 3.79 2.51–5.72 2.74 1.96–3.83 2.16 1.38–3.40
10 year risk for fatal CV event >10%b 2.79 1.34–5.84 2.50 1.36–8.52 2.78 1.10–7.03
Skin AF > median 1.21 0.82–1.79 0.718 0.857 1.46 1.04–2.05 0.705 0.460 2.18 1.32–3.59 0.715 0.504
Primary endpoint: fatal + non-fatal CVevents; first secondary endpoint: non-fatal CVevents + all-cause mortality; second secondary endpoint: all-
cause mortality
a Comparing AUCs of models 1 and 2 with and without skin AF
b Calculated with the UKPDS risk engine
10 year risk categories using
the UKPDS risk engine
Total AF < median AF > median p value No. (%)
re-classified
<10%
n 203 148 55 55/203 (27%)
Events, n (%) a 8 (3.9) 5 (3.4) 3 (5.4)
10 year event rate b 12.8 11.2 17.8 0.500
>10%
n 764 334 430
Events, n (%) 111 (14.5) 39 (11.7) 72 (16.7)
10 year event rate 47.9 38.9 55.8 0.049
All
n 967
Events, n (%) 119 (12.3)
10 year event rate 40.5
Table 4 Cardiovascular risk
re-classification for the primary
endpoint (fatal + non-fatal
cardiovascular events) in 967
patients with type 2 diabetes
from the addition of skin
autofluorescence data to the risk
predicted by the UKPDS risk
engine
a Observed events during
follow-up (approximately
3 years)
b Calculation based on the
observed incidence in approxi-
mately the first 3 years
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UKPDS risk score >10% and skin AF below the median
(38.9%). As the majority (79%) of this cohort, who were
well controlled in primary care with relatively recent onset
of type 2 diabetes, has a UKPDS risk score >10%, it is
clinically helpful to have an extra clinical tool to further
differentiate risk.
By adding skin AF categories (below and above the
median) and re-classifying patients with UKPDS risk scores
<10%, a substantial proportion of patients (27%) would be
re-classified to a higher-risk group. The incidence of CV
events in patients with a low risk calculated with the
UKPDS risk score was 59% higher if they had an AF above
the median than if the AF was below the median. Re-
classification of patients from low to high risk by AF
seems, therefore, justified and should result in re-
consideration of treatment strategies by extending or
intensifying treatment in such individuals. Skin autofluor-
escence should not result in re-classification of patients
from high risk (UKPDS risk score >10%) to low risk when
skin AF is below the median, because the incidence rate of
CV events is high in this group and ‘undertreatment’ is
undesirable.
A history of macrovascular disease and a UKPDS risk
score above 10% were significant predictors in the
multivariate Cox regression analysis for all endpoints, and
had the highest hazard ratios. Adding skin autofluorescence
to UKPDS risk score in model 1 increased the AUC by an
increment considered clinically relevant (>0.025); it was
not statistically significant for the primary endpoint because
of the sample size. For the endpoint ‘all-cause mortality’,
the increase in AUC of the model with AF was higher and
significant. In model 2, where a history of macrovascular
disease was also included, the addition of AF was not
relevant for the primary endpoint and was just relevant for
the secondary endpoint. The small contribution of AF in
this model might be due to the relation of AF to
macrovascular disease. In our previous study with cross-
sectional data we showed that AF was related to clinically
apparent vascular damage, such as macrovascular disease
[7]. The present follow-up study confirms skin AF to be a
marker of vascular damage before it becomes clinically
apparent because the incidence of CV events has increased
in the patient group with a baseline skin AF value above the
median.
The contributions of skin AF to all models were higher
for the secondary endpoints, where ‘all-cause mortality’
was included. This suggests that skin AF or AGEs might
also be involved in non-CV causes of death such as cancer.
A long-term follow-up study in a Finnish type 2 diabetes
mellitus population showed that serum levels of AGEs
were predictive for all-cause and CV mortality [16].
Other original papers on the predictive value of AGEs for
CV morbidity or mortality are scarce. However, the
mechanisms through which AGEs can result in vascular
injury have been described by extension [1, 17, 18]. A
recent study showed a pathophysiological example of
the role of AGEs in CV disease by finding increased
myocardial AGE deposition in patients with diabetes and
heart failure with reduced left ventricular ejection fraction
[19].
Despite our inclusion of patients with a history of CHD
(which is different from the UKPDS), the expected UKPDS
score event rates at 3.2 years in our group were in line with
the observed rates, confirming that the UKPDS scores were
applicable and calibrated for our group. The incidence of
new CV events in our group was twice as high in the 20%
of patients with a history of CHD as in patients without a
history of CHD. Including patients with a history of CHD
seems to be justified by daily practice where a history of
CHD is common even in those newly diagnosed with
type 2 diabetes. The UKPDS risk engine was developed
in a young group (25–65 years, mean age at diagnosis
52 years) newly diagnosed with type 2 diabetes, without
previous CV disease, identified between 1977 and 1991,
selected for participation in a clinical trial, and using the
mean of HbA1c, BP and lipid levels in the first 2 years after
diagnosis [9]. Despite the increased incidence at younger
ages, type 2 diabetes presents mainly in individuals over
60 years of age in the Netherlands; these patients often have
CHD and are already using statins or antihypertensive
agents. When blood pressure or cholesterol values from
such individuals are entered in the UKPDS risk engine, the
calculated risk score might be an underestimated risk. The























Fig. 1 Kaplan–Meier survival curves for the primary endpoint for the
four groups: group 1, AF < median and UKPDS risk score <10% (n=
144); group 2, AF > median and UKPDS risk score <10% (n=59);
group 3, AF < median and UKPDS risk score >10% (n=328); and
group 4, AF > median and UKPDS risk score >10% (n=436).
Survival was significantly different between group 4 and all other
groups, and between group 3 and group 1
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in order to adapt treatment targets. Our older patient group
with HbA1c levels comparable with those of the UKPDS
cohort but with prevalent (39%) macrovascular disease
reflects the differences between our ‘daily practice’ type 2
diabetes cohort and the UKPDS cohort.
In the present study, HbA1c was not found to add
predictive value for any of the endpoints. The contribution
of HbA1c in the prediction of increased CV risk in type 2
diabetes was illustrated in the UKPDS by an almost
twofold increase in 10 year CHD risk, and by a higher
odds ratio for fatal to non-fatal events for both myocardial
infarction and stroke [9, 20]. This seeming discrepancy
with our models that include skin AF may reflect the
relatively low mean HbA1c in our population. Another
potential explanation lies in the following concept. First,
skin AF and skin biopsy AGEs may reflect the impact of
the history of hyperglycaemic episodes in diabetes and
preceding impaired glucose tolerance better than the short-
term measure of hyperglycaemia indicated by HbA1c
(weeks). Second, AGEs are also formed during oxidative
stress via the pathway of reactive carbonyl compound
formation [18]. An earlier study found skin AF to be related
to C-reactive protein and inversely related to antioxidant
levels, suggesting that skin AF represents inflammatory as
well as hyperglycaemic episodes [21]. The DCCT-EDIC
group reported that skin collagen AGE and collagen-linked
fluorescence from skin biopsies were better predictors than
HbA1c of diabetic complications in type 1 diabetes mellitus
[2, 3]. They introduced the idea of ‘metabolic memory’—
that stable AGEs bound to long-lived proteins such as skin
collagen provide long-term (years) memory of episodes of
hyperglycaemia and oxidative stress—as an explanation for
the superiority of skin AGE as a risk predictor. The recent
long-term follow-up of glucose control in the UKPDS
cohort showed in the intensive therapy group a continued
reduction in risk for microvascular complications, myocar-
dial infarction and all-cause mortality during 10 years of
post-trial follow-up. This occurred despite the early loss of
glycaemic and HbA1c differences, and adds further support
to the above concept [22].
Some limitations of our study should be kept in mind:
the follow-up period is relatively short. Our calculations
were all based on single measurements. The effects of
regression dilution bias cannot be excluded. As for the
comparison with the UKPDS risk score, in the design of the
UKPDS the years 0–4 were excluded from the analysis, as
the mortality rates were lower in the first years of the
clinical trial. We used a cohort which had been recruited
and followed for at least 3 years before the baseline AF
measurements. Furthermore, our population size was small
compared with larger studies specifically designed to
develop risk-prediction models. This study was not pow-
ered to reach significance with the clinically relevant
increase in AUC of 0.025 by skin AF. However, relevant
increase in AUC became visible in this small cohort at this
stage of the follow-up. Finally, our results were obtained in
a predominantly white group. AF measurements in dark-
skinned persons were not considered reliable using the
prototype device in our study. Thus, the predictive results
of skin AF may not directly be extrapolated to groups with
darker skin, but probably need additional validation with
newer versions of the AGE Reader.
In conclusion, non-invasive skin AF is a clinical tool which
could be used in addition to the UKPDS risk score to identify
diabetic individuals with preclinical vascular damage who have
a particularly high risk of developing CV events. A high skin
AF value can also result in re-classification to a high-risk group
patients who are classified as ‘low risk’ according to the
UKPDS risk engine. Although many type 2 diabetes patients
are nowadays controlled tightly according to guidelines for
their classic risk factors, they still develop micro- and macro-
vascular complications. Therefore, there is a need for additional
markers to identify patients at high risk for complications.
Furthermore, risk calculators may underestimate CV risk in
patients already treated with antihypertensive or lipid-lowering
drugs. Improvement of risk-prediction strategies is important to
further reduce the incidence or progression of complications in
patients with diabetes.
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